Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

16:12
10/09/16
10/09
16:12
10/09/16
16:12

Bristol-Myers reports final primary analysis of CheckMate-026 lung cancer study

Bristol-Myers Squibb announced the final primary analysis of CheckMate -026, a trial investigating the use of Opdivo monotherapy as first-line therapy in patients with advanced non-small cell lung cancer whose tumors expressed PD-L1 greater or equal to 1%. The study was powered to assess progression-free survival for patients with greater or equal to 5% PD-L1 expression. The topline results from the study were previously disclosed and showed CheckMate -026 did not meet the primary endpoint of superior PFS compared to chemotherapy. In patients with greater than/equal to 5% PD-L1 expression, the median PFS was 4.2 months with Opdivo and 5.9 months with platinum-based doublet chemotherapy. Overall survival was 14.4 months for Opdivo versus 13.2 months for chemotherapy, and 60% of patients on the chemotherapy arm received subsequent Opdivo use after progression either through crossover or commercial access. The safety of Opdivo was consistent with the known safety profile of the drug in previous studies. Among all-treated patients, treatment-related adverse events of any grade and Grade 3/4 occurred in 71% and 18% of Opdivo-treated patients and 92% and 51% of chemotherapy-treated patients, respectively.

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

BMS

Bemis

$44.90

-0.28 (-0.62%)

20:30
06/22/17
06/22
20:30
06/22/17
20:30
Upgrade
Bemis rating change at BMO Capital »

Bemis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATUS

Altice USA

20:29
06/22/17
06/22
20:29
06/22/17
20:29
Initiation
Altice USA initiated at Pivotal Research »

Altice USA initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

BBRY

BlackBerry

$11.06

0.41 (3.85%)

, FINL

Finish Line

$12.73

0.23 (1.84%)

20:25
06/22/17
06/22
20:25
06/22/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BBRY

BlackBerry

$11.06

0.41 (3.85%)

FINL

Finish Line

$12.73

0.23 (1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 23

    Jun

NBRV

Nabriva Therapeutics

$10.50

1.19 (12.78%)

20:22
06/22/17
06/22
20:22
06/22/17
20:22
Initiation
Nabriva Therapeutics initiated at Cantor »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

WIX

Wix.com

$72.80

0.5 (0.69%)

20:20
06/22/17
06/22
20:20
06/22/17
20:20
Initiation
Wix.com initiated at Wedbush »

Wix.com initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

OCLR

Oclaro

$9.44

-0.1 (-1.05%)

20:19
06/22/17
06/22
20:19
06/22/17
20:19
Initiation
Oclaro initiated at DA Davidson »

Oclaro initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

ACIA

Acacia Communications

$41.64

0.65 (1.59%)

20:19
06/22/17
06/22
20:19
06/22/17
20:19
Initiation
Acacia Communications initiated at DA Davidson »

Acacia Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

LITE

Lumentum

$62.45

-0.05 (-0.08%)

20:19
06/22/17
06/22
20:19
06/22/17
20:19
Initiation
Lumentum initiated at DA Davidson »

Lumentum initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

LEJU

Leju

$2.46

0.07 (2.93%)

20:05
06/22/17
06/22
20:05
06/22/17
20:05
Downgrade
Leju rating change at JPMorgan »

Leju downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GCP

GCP Applied Technologies

$30.40

0.3 (1.00%)

20:04
06/22/17
06/22
20:04
06/22/17
20:04
Upgrade
GCP Applied Technologies rating change at KeyBanc »

GCP Applied Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$24.04

-0.24 (-0.99%)

19:58
06/22/17
06/22
19:58
06/22/17
19:58
Initiation
PulteGroup initiated at Credit Suisse »

PulteGroup initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$33.47

-0.5 (-1.47%)

19:58
06/22/17
06/22
19:58
06/22/17
19:58
Initiation
D.R. Horton initiated at Credit Suisse »

D.R. Horton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAA

CalAtlantic

$34.80

-0.34 (-0.97%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
CalAtlantic initiated at Credit Suisse »

CalAtlantic initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZH

Beazer Homes

$13.01

0.03 (0.23%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Beazer Homes initiated at Credit Suisse »

Beazer Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTH

Meritage Homes

$40.40

-0.4 (-0.98%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Meritage Homes initiated at Credit Suisse »

Meritage Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Toll Brothers initiated at Credit Suisse »

Toll Brothers initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$52.41

-0.84 (-1.58%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Lennar initiated at Credit Suisse »

Lennar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$22.23

-0.1 (-0.45%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
KB Home initiated at Credit Suisse »

KB Home initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MHK

Mohawk

$242.70

-0.22 (-0.09%)

19:27
06/22/17
06/22
19:27
06/22/17
19:27
Initiation
Mohawk initiated at Credit Suisse »

Mohawk initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$65.09

0.06 (0.09%)

19:27
06/22/17
06/22
19:27
06/22/17
19:27
Initiation
Fortune Brands initiated at Credit Suisse »

Fortune Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

JELD-WEN Holding

$34.60

-0.29 (-0.83%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
JELD-WEN Holding initiated at Credit Suisse »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$52.75

-1 (-1.86%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Installed Building Products initiated at Credit Suisse »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OC

Owens Corning

$66.42

-0.85 (-1.26%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Owens Corning initiated at Credit Suisse »

Owens Corning initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$195.16

1.35 (0.70%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Whirlpool initiated at Credit Suisse »

Whirlpool initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$38.82

0.06 (0.15%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Masco initiated at Credit Suisse »

Masco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.